Dr. Daniel Singer Discusses Atrial Fibrillation Stroke Prevention Anticoagulants — Video

Dr. Daniel Singer Discusses Atrial Fibrillation Stroke Prevention Anticoagulants — Video

By Mellanie True Hills

January 25, 2012

  • Summary: In this video interview, Dr. Daniel Singer of Harvard discusses the information about new anticoagulants for atrial fibrillation stroke prevention that he presented at the Boston Atrial Fibrillation Symposium, which included dabigatran, rivaroxaban, apixaban, and edoxaban.
  • Reading and watching time is approximately 5–6 minutes

Dr. Daniel Singer, of the Harvard Medical School and Harvard School of Public Health, led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium.

He provided an update on rivaroxaban (Xarelto), which was recently approved by the FDA, and talked about the results of the two trials of apixaban (Eliquis), AVERROES and ARISTOTLE, against aspirin and warfarin, respectively. He also mentioned edoxaban, which should finish trials in 2012, and that we now have a year of results in clinical practice with dabigatran (Pradaxa). He also mentioned that the new drugs have all shown better results than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the brain). He confirmed that patients will have a lot of new choices soon, but that cost will continue to be an issue.

View the video interview with Dr. Singer (4 ½ minutes):

Previous video interview with Dr. Singer — from Boston AF Symposium 2011

About Daniel E. Singer, MD:

Professor of Medicine, Harvard Medical School
Professor, Department of Epidemiology, Harvard School of Public Health
Chief, Clinical Epidemiology Unit, Massachusetts General Hospital

Dr. Singer is an internationally recognized leader in the field of stroke prevention in atrial fibrillation (AF). With his colleagues, Dr. Singer has helped establish the efficacy of anticoagulant therapy in AF, identified risk factors for stroke, and defined the optimal range of anticoagulation in AF. He was the chair and lead author of the Atrial Fibrillation chapter in the 2008 American College of Chest Physicians Consensus Conference on Antithrombotic and Thrombolytic Therapy. He has also conducted extensive investigations into the impact of hyperglycemia, impaired glucose tolerance, and diabetes on the development of vascular disease.

Dr. Singer was the 2003 recipient of the John M. Eisenberg Award, the Society of General Internal Medicine’s highest award for career achievements in research. In addition, Dr. Singer was awarded the 2008 C. Miller Fisher Award from the New England chapter of the American Heart Association/American Stroke Association for his research on stroke prevention. Dr. Singer also received the 2007-2008 Harvard Medical School William Silen Lifetime Achievement in Mentoring Award.

See Dr. Singer’s profiles and contact info:

Video Transcript: Coming Soon

Disclaimer: Companies mentioned on this site may or may not be donors to StopAfib.org but no one receives favored treatment in coverage as atrial fibrillation patients are our first priority.